Clinical trial · Observational
PET-MR-PSA Prostate Cancer Recidive Study
18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
NCT02562131CI-TRIAL-00090697PET-MR-PSAactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging session. The aim of this study is to evaluate the sensitivity and specificity of simultaneous 18F-Fluciclovine PET/MRI for detection of recurrent prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Detection of recurrent prostate cancer by simultaneous 18F-Fluciclovine PET/MRI.
- timeFrame
- 10 years
- description
- Relevant patient information will be collected until 2027, 10 years after the last PET/MRI scan.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * the criteria for biochemical relapse in accordance with the European Association of Urology (EAU) guidelines on prostate cancer must be fulfilled (two consecutive measurements with PSA \> 0.2 ng/ml following radical prostatectomy or PSA \> 2.0 ng/ml above the nadir following definitive radiotherapy) * potential candidates for salvage treatment based on age and co-morbidity. Exclusion Criteria: * general contra-indications for a PET/MRI exam (pacemaker, aneurysm clips, any form of metal in the body, or severe claustrophobia) * impaired renal function defined as estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m2
References
Publications (0)
Data not yet available
No reference posted for this study.